NCT06166667

Effect of Fecal Capsule on Chronic Kidney Disease (CKD)

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: Shanxi Provincial People's Hospital · Other Government
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Accepted

Summary

By collecting blood, urine and stool samples before and after oral Enterobacteriaceae capsule (FMT) from CKD subjects, we investigated the role and related mechanisms of gut microecology in the development of CKD using a combination of metagenomic sequencing, metabolomic analysis and flow cytometry.

Detailed description

Patients involved in the trial received 16 capsules of Enterobacteriaceae (one course) on days 1, 8, and 15, which were provided by Dongyuan Yikang company. Patients were prohibited from taking antibiotics such as amoxicillin and Cefalexin during the trial.

Conditions

• Renal Insufficiency, Chronic

Interventions

Type	Name	Description
PROCEDURE	Fecal Microbiota Transplant（FMT）	Patients involved in the trial received 20 capsules of Enterobacteriaceae (one course) on days 1, 8, and 15, which were provided by Dongyuan Yikang company. Patients were prohibited from taking antibiotics such as amoxicillin and Cefalexin during the trial.

Timeline

• Start date: 2023-03-01
• Primary completion: 2023-12-31
• Completion: 2023-12-31
• First posted: 2023-12-12
• Last updated: 2025-05-16

Locations

1 site across 1 country: China